MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today its financial results for the year ended December 31, 2009. The Company reported total revenues from continuing operations of $428 million for 2009 compared to revenues of $379 million for 2008, a 13% increase over the prior year. Total revenues from continuing operations for the three months ended December 31, 2009 were $124 million, compared with $98 million for the same period last year, a 26% increase over the prior year. Total worldwide net sales of Tarceva® (erlotinib) for the three and twelve months ended December 31, 2009, as reported to the Company by its collaborator Roche, were approximately $333 million and $1.2 billion, respectively, representing a 7% growth in annual sales and a 17% increase in sales for the fourth quarter of 2009 compared to the same periods last year.
